A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy
Wei Liu(London Health Sciences Centre), Glenn Bauman(Thomas Jefferson University Hospital), Susan Archer(Western University), Irina Rachinsky(Western University), Katherine Zukotynski(Unknown), Tracy Sexton(London Health Sciences Centre), Andrew Loblaw(Sunnybrook Health Science Centre), Gregory R. Pond(Juravinski Hospital), Michael Lock(London Health Sciences Centre), Louise Emmett(St Vincent's Hospital Sydney), Ur Metser(Princess Margaret Cancer Centre), Joelle Helou(Princess Margaret Cancer Centre), Robert J. Wolfson(University of Toronto), Hans T. Chung(University of Toronto), Alejandro Berlín(University of Toronto), Peter Chung(Princess Margaret Cancer Centre), Gerard Morton(Sunnybrook Health Science Centre), Colm Boylan(St. Joseph’s Healthcare Hamilton), Anil Kapoor(People’s University)
International Journal of Radiation Oncology*Biology*Physics
November 12, 2019
Cited by 67
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.2k
Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial
|Journal of Clinical Oncology|2014|1.1k
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594